| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.009 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.15 | 0.01 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.02 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.08 | 0.03 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | -0.074 | 0.03 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.077 | 0.03 |